Article: Epirubicin, vinorelbine, and cisplatin are effective in advanced breast cancer.

2004 APR 9 - (NewsRx.com & NewsRx.net) -- Combined epirubicin, vinorelbine, and cisplatin resulted in an 84% objective response rate for patients with advanced breast cancer.

"Our objective was to evaluate the activity and safety of the combination of cisplatin, epirubicin and vinorelbine (CEV) in advanced breast cancer patients. Patients with advanced breast cancer, locally advanced or metastatic, received epirubicin 75 mg/m[superscript]2 and cisplatin 50 mg/m[superscript]2 on day 1, and vinorelbine 25 mg/m[superscript]2 on day 5. Cycles were repeated every 3 weeks," investigators in Italy report.

"A total of 35 patients were treated. Thirty-one ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!